FAIR VALUE - Narrative (Details)
|
1 Months Ended |
12 Months Ended |
|
May 31, 2020
USD ($)
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Short-term contingent consideration |
|
$ 14,500,000
|
$ 6,776,000
|
| Long-term contingent consideration |
|
23,159,000
|
31,776,000
|
| Level 3 | Contingent consideration | Costs and expenses |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Changes in fair value |
|
$ (3,914,000)
|
(1,500,000)
|
| Revenue volatility |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration, measurement input |
|
0.35
|
|
| Discount rate |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration, measurement input |
|
0.070
|
|
| Credit spread |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration, measurement input |
|
0.052
|
|
| Zyla Life Sciences |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration, revenue percentage |
20.00%
|
|
|
| INDOCIN |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration liability |
|
$ 37,500,000
|
38,400,000
|
| Short-term contingent consideration |
|
14,500,000
|
6,800,000
|
| Long-term contingent consideration |
|
23,000,000
|
31,600,000
|
| INDOCIN | Zyla Life Sciences | Iroko |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent payment consideration, future royalties covenant, product net sales (over) |
$ 20,000,000
|
|
|
| CAMBIA |
|
|
|
| Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items] |
|
|
|
| Contingent consideration liability |
|
$ 200,000
|
$ 200,000
|